TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report released on Sunday morning. The firm issued a hold rating on the stock.

TherapeuticsMD Trading Down 1.2 %

TXMD opened at $1.67 on Friday. The business’s 50-day simple moving average is $1.75 and its 200-day simple moving average is $1.93. TherapeuticsMD has a one year low of $1.43 and a one year high of $3.15.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter. The company had revenue of $0.23 million during the quarter.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Clearline Capital LP lifted its position in TherapeuticsMD by 18.9% during the 2nd quarter. Clearline Capital LP now owns 636,622 shares of the company’s stock worth $1,025,000 after acquiring an additional 101,282 shares during the period. Prosperity Consulting Group LLC acquired a new stake in TherapeuticsMD during the 1st quarter worth approximately $56,000. Finally, ADAR1 Capital Management LLC acquired a new stake in TherapeuticsMD during the 4th quarter worth approximately $612,000. Hedge funds and other institutional investors own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.